Table 1.
Patient description
| Patient information | |||||
|---|---|---|---|---|---|
| EDSS score | |||||
| Number | Female/male ratio | Age | <3 | >3 | |
| HC | 9 | 5 : 4 | Median: 30 | NA | NA |
| Range: 22–47 | |||||
| RRMS− therapy | 10 | 7 : 3 | Median: 40 | n = 4 | n = 5 |
| Range: 18–54 | Mean = 2 | Mean = 5·5 | |||
| RRMS+ therapy* | 6 | 4 : 2 | Median: 41 | n = 5 | n = 1 |
| Range: 29–46 | Mean = 4 | Mean = 1·7 | |||
| SPMS | 10 | 7 : 3 | Median: 46 | n = 9 | |
| Range: 25–69 | Mean = 6 | ||||
*
Patients on IFN-β therapy for at least 3 months. Patients were seen in the multiple sclerosis clinic at the Ottawa Hospital General Campus. Informed written consent was obtained from each patient.